2019/03/22

Safety Assessment of Agrichemicals Ina Research Inc. supports a comprehensive range of toxicity tests required in applications for registration of new agricultural chemicals, starting from the screening stage. As a GLP-compliant, AAALAC-accredited* facility, our in vivo/in vitro tests also comply with OECD guidelines and country-specific regulations related to applications and safety assessments for new agricultural chemicals. Upon your request, we also offer consulting services on toxicity evaluation taking into account the regulations of each country.      　　　  *Association for Assessment and Accreditation of Laboratory Animal Care International General Toxicity Tests (compliant with OECD Test Guidelines) 　     Observations, Examinations and Measurements:           ・Clinical observations, body weights, food and water consumption, ophthalmology, urinalysis,            hematology, clinical chemistry, gross pathology,

2019/03/22

Safety Assessment of Chemicals Ina Research conducts safety assessment of chemicals to form the basis for GHS classification, SDS preparation, REACH registration, etc. Our laboratory was the first facility in Japan to be fully-certified by AAALAC International, an international authority on animal welfare. Studies Acute toxicity (oral, dermal)Repeated dose toxicity (subchronic/chronic)In vivo irritation (skin, eyes)In vitro irritation (human skin model, human cornea model)Genotoxicity (Ames test, chromosomal aberration test, micronucleus test)Sensitization (Maximization method, etc.)Reproductive toxicityCarcinogenicity Studies are conducted in compliance with OECD Guidelines.Our experienced researcher will propose appropriate study designs for your goal. Screening Tests We conduct initial screening for acute toxicity, irritation (vivo / vitro) and genotoxicity (Ames), etc. at

2019/03/22

Safety Assessment of Pharmaceuticals and Medical Devices Toxicology Studies for Pharmaceuticals Ina Research offers complete support services for a full-range of non-clinical toxicity studies for pharmaceutical development, from the screening stage to preparation for clinical trials. We can propose the appropriate study design, using minimal amounts of test article to best suit your developmental needs. The various tests required for entering Phase I clinical trials, including genotoxicity and safety pharmacology studies, can be completed, from initial testing to final report submission, in as little as 8 months. Our team of experienced researchers includes certified toxicologists, pathologists and doctorate holders, and is supported by certified laboratory animal technicians. General Toxicity Genotoxicity Reproductive and Developmental

2019/03/22

SEND Pharmaceuticals/Medical Devices Chemicals Agrochemicals Efficacy Studies Health Food Studies Analysis Clinical Pathology Pathology Metabolism & Chemical Analysis Environmental Equipment Quality Assurance Published Papers Translation Archives Seminar Archives

2018/11/10

With the goal of developing a new treatment for myocardial infarction, Ina Research has been pursuing a joint research project with a research team led by Associate Professor Yuji Shiba of the Institute for Biomedical Sciences (Director: Naoto Saito), Interdisciplinary Cluster for Cutting Edge Research at Shinshu University (hereinafter referred to as the “Shiba research team”) (as reported in a press release dated August 17, 2015). Today, I am pleased to inform you that the project’s achievements have been recognized and an article written by Associate Professor Yuji Shiba as lead author, and an employee of Ina Research as coauthor, will be published in the British multidisciplinary scientific journal Nature

2018/11/09

Ina Research, Japan SLC, and DNA Link join forces for the effective use of PDX mouse modelsFirst-ever production and commercial use in Japan July 2018, Ina Research, Japan SLC, and Korea’s DNA Link launched a joint project for the effective use of “PDX (Patient derived xenograft) mouse models,” in which patient-derived cancer cells are transplanted into the living body of a mouse for the development of pharmaceutical products. Japan SLC, a provider of laboratory animals, will produce PDX models using cancer cells of Asian patients provided by DNA Link, which owns the library of human cancer cells.Ina Research will then use the optimal PDX model to conduct drug efficacy tests

2018/11/08

Shinshu University establishes a domestic base in Ina toward the practical application of new cancer treatment “CAR-T cell therapy” Shinano Mainichi News as of September 21, 2018 Translated by Ina Research Shinshu University (headquartered in Matsumoto City) will establish a “Gene/Cell Therapy Research and Development Center” (tentative name), a facility for safety studies of “CAR-T cell therapy,” a new immune cell therapy for cancer, at Ina Research Inc. (Ina City) according to a source on September 20. The center will also provide services including safety studies of medical products. The center is planned to become fully operational in fiscal 2019. It was initiated as a government-commissioned project aimed at improving